Base Year
Historical Year
Forecast Year
The erythema market size in the 7 major markets was valued at USD 178.9 million in 2023, driven by rising incidence of cancer across the major markets. The market is expected to grow at a CAGR of 5.8% during the forecast period of 2024-2032, with the values likely to rise from USD 189.3 million in 2024 to USD 297.7 million by 2032.
Erythema is a wide category of skin condition, characterized by abnormal redness on the skin or mucous membranes. Hyperemia (increased blood) in superficial capillaries is one of the major causes of the condition. It may be an inflammatory response to an infection, massage, drug or medication, acute radiation syndrome, and mercury toxicity, among others. Erythema is of multiple types, with the most common symptoms being circular red bumps, itchiness, blisters, fever, or joint pain.
Erythema is a common side effect of chemotherapy; therefore, the rising incidence of cancer cases has directly impacted the erythema market growth in recent years. Consequently, there has been significant emphasis on alleviating the chemotherapy associated symptoms with the help of novel therapeutics. In January 2023, it was revealed that high doses of vitamin D may function as an effective treatment alternative for the condition.
Erythema can be classified into several categories, including erythema multiform, nodosum, and chronicum migraines, among others. The treatment and management differ from condition to condition. Minor diseases are commonly treated with oral antihistamines or topical corticosteroids, whereas severe conditions are treated through systemic steroids.
To tackle recurrent erythema multiform (REM), several trials and developments are going on. As per studies, Azathioprine is one of the many immunosuppressive agents reported to be helpful for unresponsive REM cases to other treatments. With increasing understanding of the human physiology and growing technical advancements, the erythema market value is projected to grow in the forecast period.
Market Breakup by Type
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
With a significance on skin health and meeting the high erythema market demand, the United States has experienced critical developments in recent years. The enhancements can be attributed to the presence of key healthcare companies and a well-established infrastructure, contributing extensively to market value.
The rising prevalence of skin conditions drives the market growth in Europe as well. Countries like the United Kingdom, Italy, Germany, and France are some of the key regions offering quality treatments, owing to the presence of prominent research and academic institutions. Mergers and collaborations between key pharmaceutical companies and academic organizations is another important factor for the market size.
The Asia Pacific region, particularly countries like Japan, China, India, and South Korea are also affected by a huge demand. With an affluential traditional medicinal therapy history, the countries are also developing herbal medications for the condition. On the other hand, there have been continuous efforts to improve the healthcare infrastructure for better research and development. Therefore, the region is anticipated to contribute significantly to the erythema market share globally as well.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 178.9 million in 2023, driven by growing incidence of cancer across the globe.
The market is anticipated to grow at a CAGR of 5.8% during the forecast period of 2024-2032, likely to reach a market value of USD 297.7 million by 2032.
The market demand is driven by the increasing drug developments and trials to offer better patient outcomes.
The market trend involves the increasing focus on developing personalised medicine for patients. High dosage of vitamin D is being administered to patients to minimise the chemotherapy associated side effects.
Based on types, the market is divided into erythema multiforme, nodosum, ab igne, chronicum migrans, induratum, infectiosum, marginatum, toxicum, gyratum repens, palmar erythema and annulare centrifugum.
Common mechanism of action includes antibiotics, antihistamines, analgesics, NSAIDs, corticosteroid, antiviral, antifungal and antibacterial.
Major end users include hospitals, clinics, and ambulatory clinics, among others.
The route of administration can be oral, topical, intravenous among others.
The major regions of the market include the United States, Japan, EU-4, which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are GSK plc. (U.S.), F. Hoffmann-La Roche Ltd., Novartis AG, Astrazeneca, Pfizer Inc., Bristol-Myers Squibb Company, Sanofi, Amgen Inc., AB Sciences, Eisai Co., Ltd., Regeneron Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Bausch Health Companies Inc., and Enzon Pharmaceuticals.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share